Informace o publikaci

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project

Autoři	ČEŠKA Richard LATKOVSKIS Gustavs EZHOV Marat V. FREIBERGER Tomáš LALIC Katarina MITCHENKO Olena PARAGH Gyorgy PETRULIONIENE Zaneta POJSKIC Belma RASLOVA Katarina SHEK Aleksandr B. VOHNOUT Branislav ALTSCHMIEDOVÁ Tereza TODOROVOVÁ Veronika
Rok publikování	2019
Druh	Článek v odborném periodiku
Časopis / Zdroj	CURRENT ATHEROSCLEROSIS REPORTS
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	http://dx.doi.org/10.1007/s11883-019-0797-3
Doi	http://dx.doi.org/10.1007/s11883-019-0797-3
Klíčová slova	Familial hypercholesterolemia; FH; ScreenPro FH; Evolocumab; Alirocumab; LDL-C
Popis	Purpose of ReviewFamilial hypercholesterolemia (FH) is often perceived and described as underdiagnosed and undertreated, though effective treatment of FH is available. Owing to the mentioned facts, it is ever more imperative to screen and treat FH patients. Subsequent to the identification of patients, the project focuses on the improvement of their prognoses. The ScreenPro FH project was established as a functional international network for the diagnosis, screening, and treatment of FH. Individual countries were assigned goals, e.g., to define the actual situation and available treatment. With central support, more centers and countries participated in the project. Subsequently, individual countries reported the results at the beginning and end of the project. Collected data were statistically evaluated.Recent FindingsThe increasing number of patients in databases, from 7500 in 2014 to 25,347 in 2018, demonstrates the improvement in overall effectiveness, as well as an increase in the number of centers from 70 to 252. Before all, LDL-C decreased by 41.5% and total cholesterol by 32.3%. As data from all countries and patients were not available at the time of the analysis, only those results from 10 countries and 5585 patients at the beginning of the project and at the time of writing are included.SummaryOur data are quite positive. However, our results have only limited validity. Our patients are far from the target levels of LDL-C. The situation can be improved with the introduction of new therapy, PCSK9-i, evolocumab, and alirocumab. International cooperation improved the screening of FH and finally led to an improvement in cardiovascular risk.